This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
SAGE's Huntington's Disease Study Meets Primary Endpoint
by Zacks Equity Research
The phase II SURVEYOR study evaluating SAGE's dalzanemdor as a potential treatment for patients with cognition dysfunction caused by Huntington's disease meets its primary endpoint.
Eli Lilly (LLY) Veteran Anat Ashkenazi to Join Alphabet as CFO
by Zacks Equity Research
Eli Lilly (LLY) CFO Anat Ashkenazi joins Google's parent company Alphabet as CFO and senior vice president, effective from Jul 31, 2024
Here's Why You Should Consider Buying Bioventus (BVS) Stock
by Zacks Equity Research
Here, we discuss some reasons why buying Bioventus (BVS) stock now may turn out to be a prudent move.
Is Acrivon Therapeutics, Inc. (ACRV) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Acrivon Therapeutics, Inc. (ACRV) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.
Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock
by Zacks Equity Research
Here, we discuss some reasons why buying Acrivon Therapeutics (ACRV) stock now may turn out to be a prudent move.
5 Small Drug Stocks to Buy From a Recovering Industry
by Kinjel Shah
Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.
Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Acrivon Therapeutics, Inc. (ACRV) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Is a Surprise Coming for Acrivon Therapeutics (ACRV) This Earnings Season?
by Zacks Equity Research
Acrivon Therapeutics (ACRV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Catalyst (CPRX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Catalyst's (CPRX) revenues in the first quarter of 2023 are expected to have been driven by Firdapse sales. Updates on generic competition and the commercial launch of Fycompa are expected.